Eagle Pharmaceuticals (EGRX) Updates Q3 Earnings Guidance

Share on StockTwits

Eagle Pharmaceuticals (NASDAQ:EGRX) updated its third quarter earnings guidance on Tuesday. The company provided earnings per share guidance of $1.18 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.97. The company issued revenue guidance of $51 million, compared to the consensus revenue estimate of $55.23 million.

A number of equities research analysts recently weighed in on the company. Cantor Fitzgerald cut Eagle Pharmaceuticals from an overweight rating to a neutral rating in a report on Thursday. Piper Jaffray Companies cut Eagle Pharmaceuticals from an overweight rating to a neutral rating and lowered their target price for the company from $82.00 to $54.00 in a report on Wednesday. ValuEngine cut Eagle Pharmaceuticals from a buy rating to a hold rating in a report on Wednesday. Zacks Investment Research cut Eagle Pharmaceuticals from a hold rating to a strong sell rating in a report on Thursday, October 18th. Finally, BidaskClub upgraded Eagle Pharmaceuticals from a hold rating to a buy rating in a report on Saturday, September 29th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and three have given a buy rating to the stock. Eagle Pharmaceuticals presently has a consensus rating of Hold and an average target price of $80.83.

NASDAQ:EGRX traded up $2.38 during trading hours on Thursday, reaching $51.62. 391,172 shares of the company traded hands, compared to its average volume of 268,480. The stock has a market cap of $715.16 million, a PE ratio of 15.32 and a beta of 1.32. The company has a debt-to-equity ratio of 0.22, a quick ratio of 4.09 and a current ratio of 4.22. Eagle Pharmaceuticals has a 1-year low of $46.88 and a 1-year high of $85.66.

Eagle Pharmaceuticals (NASDAQ:EGRX) last announced its earnings results on Thursday, November 1st. The specialty pharmaceutical company reported $1.18 EPS for the quarter, beating analysts’ consensus estimates of $0.91 by $0.27. The firm had revenue of $51.34 million for the quarter, compared to analysts’ expectations of $52.70 million. Eagle Pharmaceuticals had a return on equity of 19.71% and a net margin of 13.81%. Eagle Pharmaceuticals’s quarterly revenue was down 18.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.22 EPS. As a group, equities research analysts predict that Eagle Pharmaceuticals will post 1.96 earnings per share for the current fiscal year.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL).

Featured Story: Do You Need a Fiduciary?

Earnings History and Estimates for Eagle Pharmaceuticals (NASDAQ:EGRX)

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply